Phathom Pharmaceuticals, Inc. (PHAT) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Phathom Pharmaceuticals, Inc. (PHAT).

Download StockRank on Google Play Download StockRank on the App Store

Equity Overview

Price & Market Data

Price: $9.31

Daily Change: +$0.63 / 6.77%

Daily Range: $8.79 - $10.06

Market Cap: $656,252,480

Daily Volume: 2,195,017

Performance Metrics

1 Week: 10.07%

1 Month: 0.32%

3 Months: 291.7%

6 Months: 48.26%

1 Year: -15.01%

YTD: 15.76%

Company Details

Employees: 427

Sector: Health technology

Industry: Pharmaceuticals: major

Country:

Details

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Selected stocks

Allete, Inc. (ALE)

ReNew Energy Global plc (RNW)

Algonquin Power & Utilities Corp. (AQN)